EC DOPARL

This brand name is authorized in Japan.

Active ingredients

The drug EC DOPARL contains a combination of these active pharmaceutical ingredients (APIs):

`1`	Levodopa UNII `46627O600J` - LEVODOPA
	According to the current understanding, the symptoms of Parkinson’s disease are related to depletion of dopamine in the corpus striatum. Dopamine does not cross the blood-brain barrier. Levodopa, the precursor of dopamine, crosses the blood brain barrier and relieves the symptoms of the disease.
	Read more about Levodopa
`2`	Benserazide UNII `B66E5RK36Q` - BENSERAZIDE HYDROCHLORIDE
	Benserazide (also called Serazide or Ro 4-4602) is a peripherally acting aromatic L-amino acid decarboxylase or DOPA decarboxylase inhibitor, which is unable to cross the blood–brain barrier.
	Read more about Benserazide

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
JP	医薬品医療機器総合機構	1169100F1052

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.